4006 POSTER Gene profile predicts protection from radio-induced late rectal bleeding in prostate cancer

Sunitinib, pazopanib, sorafenib, axitinib and bevacizumab are the five recommended antiangiogenic agents in first-line therapy for metastatic renal cell carcinoma (mRCC). Because these drugs underwent simultaneous clinical development, no direct efficacy and safety comparison was ever conducted, thus preventing optimal therapy choices.We performed a traditional and network meta-analysis to evaluate the efficacy and safety of mRCC-recommended...